Research onlyGrowth hormoneSubcutaneousEvidence 3/5

Ipamorelin

Also known as: NNC 26-0161

Selectively stimulates pituitary growth hormone release without significant cortisol or prolactin elevation seen with older GHRPs.

Read guide Buy / compare source

Drug class

Selective GH secretagogue (GHRP)

Primary targets

GHSR / ghrelin receptor

Dose reference

100–300 mcg per injection (research)

Half-life

~2 hours

Developer / origin

Novo Nordisk (original)

Reference year

1998

Evidence score

3/5 - Limited human pharmacology

Evidence 3/5

Limited human pharmacology

Ipamorelin has early pharmacology and human PK/PD evidence for GH release, but no approved indication or robust long-term outcome data.

Limited human pharmacology or small clinical evidence.

Evidence basis

Human PK/PD study
Early GH secretagogue pharmacology
No approved indication

Key references

How to read this entry

Dose references and half-life values are pulled from trial protocols, labels, reviews, or published summaries where available. They are context for research and comparison, not a personal dosing recommendation.

Status matters: approved drugs have regulated indications; investigational compounds are still being studied; research-only peptides do not have established human dosing, safety, or efficacy for consumer use.

Ipamorelin guides

Read the matching guide or adjacent research pages for more context.

Ipamorelin vs Sermorelin: Growth Hormone Peptides ComparedIpamorelin and sermorelin both stimulate growth hormone release, but they work through different receptors and have very different regulatory histories.Sermorelin: Complete Guide to the GH-Releasing Peptide (2026)Sermorelin is a GHRH (growth-hormone-releasing hormone) analog. It's not a GLP-1 despite being often searched alongside them. Here's what sermorelin actually does and where it stands legally.

Compare with related peptides

Stay inside the same research category and compare mechanism, status and evidence quality.

CJC-1295

DAC:GRF

3/5

Growth hormoneResearch only

Long-acting growth-hormone-releasing hormone analog. The DAC variant binds serum albumin to extend half-life and sustain GH/IGF-1 elevation.

Details

Tesamorelin

Egrifta

5/5

Growth hormoneApproved

Stabilized GHRH analog. Approved for reduction of excess visceral abdominal fat in HIV-associated lipodystrophy.

Details

Category hub

Open the category page for the full comparison table and FAQ.

Growth Hormone Peptides

Compare growth hormone peptides including ipamorelin, CJC-1295 and tesamorelin by GH-axis mechanism, approval status, half-life and evidence score.